Ask AI
ProCE Banner Activity

Datopotamab Deruxtecan in Advanced NSCLC With Actionable Genomic Alterations: TROPION-Pan Tumor01 Phase I Trial Subset Analysis

Slideset Download
Conference Coverage
In this phase I study subset analysis, datopotamab deruxtecan demonstrated antitumor activity and manageable toxicity in patients with heavily pretreated advanced NSCLC with actionable genomic alterations.

Released: September 30, 2021

Expiration: September 29, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc